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required for the role of corticosteroids in the treatment ofCohort study of the treatment of severe HIV-associated ne-
HIVAN.phropathy with corticosteroids.
Background. Human immunodeficiency virus-associated ne-
phropathy (HIVAN) results in rapidly progressive azotemia.
The effectiveness and safety of corticosteroids in the treatment
Human immunodeficiency virus-associated nephropa-of HIVAN, however, remains controversial.
thy (HIVAN) accounts for approximately 1% of patientsMethods. We conducted a retrospective cohort study of pa-
tients with biopsy-proven HIVAN and progressive azotemia entering the end-stage renal disease (ESRD) program
who were eligible for corticosteroid treatment and who had no in the United States [1]. Increasing evidence suggests that
clinical or histologic evidence of an alternative cause of acute HIVAN is a manifestation of advanced HIV infection [2]renal failure. Selected patients were treated with 60 mg of
and that in the absence of effective treatment, the inci-prednisone for one month, followed by a several-month taper.
dence of HIVAN may be expected to rise as the numberResults. Twenty-one eligible patients were identified. Thir-
teen subjects had received corticosteroid treatment, whereas of susceptible long-term HIV survivors increases. Cur-
eight had not. The mean serum creatinine was 6.2 and 6.8 rently, in the United States, HIVAN is the third leading
mg/dL, respectively (P . 0.05). The relative risk (95% CI) for cause of ESRD in African Americans between the agesprogressive azotemia with corticosteroid treatment at three
of 20 and 64 [3]. The disease usually results in nephrotic-months was 0.20 (0.05, 0.76, P , 0.05). This association re-
range proteinuria and unrelenting progression to ESRD,mained significant despite adjustment in separate logistical re-
gression analyses for baseline creatinine, 24-hour proteinuria, often within months of presentation [4–6]. Several re-
CD4 count, history of intravenous drug use, hepatitis B, and ports have suggested benefit in the treatment of HIVAN
hepatitis C. In an additional logistic regression model, using with corticosteroids [7–10], a strategy of benefit in thebackward stepwise selection of the previously mentioned co-
treatment of non–HIV-related focal segmental glomeru-variates, only corticosteroid treatment (P 5 0.02) and baseline
losclerosis [11]. However, concern over the potential ad-serum creatinine (P 5 0.10) were retained within the model. In
the corticosteroid-treated group, the mean level of proteinuria ministration of moderately high-dose corticosteroids to
decreased by 5.5 g/24 hour (P 5 0.01). On long-term follow- already immune compromised subjects, as well as a de-
up, there was no significant difference in the incidence of hospi-
gree of therapeutic nihilism, has resulted in the infre-talizations (1 per 2.1 vs. 1 per 2.3 patient months) or of serious
quent use of corticosteroids in this setting.infections (1 per 2.6 vs. 1 per 2.3 patient months), but there
was a significantly longer duration of hospitalization in the In view of the historically poor survival of HIV-infected
corticosteroid-treated group (3.2 vs. 2 days per patient month). patients on dialysis [6, 12], early reports of the benefit
At six months, only one of the non–corticosteroid-treated pa- of corticosteroid therapy, and the absence of any alterna-
tients but seven of the corticosteroid-treated group continued
tive definitive treatment, since 1994 we have offeredto have independent renal function (P 5 0.06). Three of the
corticosteroid therapy to selected patients with biopsy-corticosteroid-treated group continued to have independent
function at two years of follow-up. proven HIVAN. This was done with the understanding
Conclusion. A limited course of corticosteroid therapy in that the treatment, although clinically justifiable, was
selected patients was beneficial and safe. Further research is not validated. Renal biopsies were performed as part of
routine clinical practice for diagnostic and prognostic
reasons. As not all of the nephrologists within our divi-Key words: azotemia, dialysis, infection, end-stage renal disease, viral
infection, nephrotic range proteinuria. sion treated HIVAN patients with corticosteroids, many,
but not all, patients with biopsy-proven HIVAN, whoReceived for publication June 17, 1999
met treatment criteria, had corticosteroid therapy rec-and in revised form January 13, 2000
Accepted for publication March 23, 2000 ommended to them. We conducted the following histori-
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and complication rate for the patients who received corti- infection was calculated from the time of renal biopsy
to either the last known contact or until the start ofcosteroid treatment with those who did not. Although
the selection of patients for corticosteroid therapy in dialysis. Renal histology was reported by one of two renal
pathologists with extensive experience in the diagnosis ofthis analysis is obviously nonrandom, the influence of
selection bias on patient outcome is limited by the uni- HIVAN. The renal biopsy reports were reviewed, with
the presence of relevant features described as being ei-formly poor renal prognosis, in the absence of treatment,
for patients with biopsy-proven HIVAN and advanced ther of moderate or advanced severity noted; a more
detailed analysis of the biopsies was not undertaken, asrenal insufficiency.
the wide variability of pathological findings in the setting
of such a limited sample size would have made meaning-
METHODS
ful analysis impossible. Patients’ long-term renal out-
Potential subjects were identified by a computerized come was ascertained as of their last known hospital or
search of the Johns Hopkins Hospital renal pathology clinic encounter.
database between the years 1994 and 1997 using the key
words HIVAN and HIV. To be eligible for inclusion in Statistical analysis
this analysis, subjects were required to have had histo- The distribution of variables was examined and nor-
logic evidence of HIVAN, as outlined by D’Agati and mality assessed using the Shapiro–Wilks test. Distribu-
Appel [5], as their primary renal diagnosis and to have tions were described as means and standard distributions
been without clinical or histological evidence of an alter- or medians and intraquartile range as appropriate. The
native disease process causing acute renal failure such accuracy of any outlying values was double checked
as acute tubular necrosis or acute interstitial nephritis. against the original data sources. The patients were di-
Patients were required to have azotemia with a serum vided into two groups depending on whether they had
creatinine of greater than 2 mg/dL, to have no evidence received corticosteroid therapy. Renal outcome at three-
of active infection, and, in the case of intravenous drug months postbiopsy was dichotomized by comparing the
users, to be abstinent from all illicit drug use. Patients follow-up with the baseline creatinine level, into either
who were already on dialysis at the time of renal biopsy progressive or nonprogressive azotemia. The crude rela-
or who did not have a renal biopsy within the month tive risk of progressive azotemia in the setting of cortico-
prior to commencing corticosteroids were excluded from steroid treatment was calculated, with 95% CI estimated
the study. Patients were treated with 60 mg of prednisone using the method of Katz et al [13]. A sensitivity analysis
for one month, followed by a planned gradual taper over was conducted excluding the corticosteroid-treated pa-
approximately two to four months. Given the limited tients who had atypical histologic features on light mi-
safety data of corticosteroid therapy available at the croscopy. The association of corticosteroids with renal
time, prior to 1996 we did not retreat patients who re- outcome was adjusted for individual confounding vari-
lapsed during or following corticosteroid withdrawal. ables using separate logistic regression models. In addi-
The relevant clinical data were abstracted from the tion, the most concise logistic regression model for de-
subject’s nephrology clinic notes, with additional data termining the effect of corticosteroids on renal outcome
obtained by review of the infectious disease clinic re- was generated by using a backward stepwise selection
cords, the main hospital record, the computerized record of the previously mentioned variables. The incidence
of Johns Hopkins Hospital emergency room visits, and of complications between the corticosteroid-treated and
discharge summaries from hospitalization at other hospi- nontreated groups was assessed using the chi-square test
tals. For the purpose of the study, the serum creatinine [14]. In all analyses, a two-sided, type 1 error rate of
measured at the time of renal biopsy is taken as the 0.05 was used. Regression analyses were performed using
patient’s baseline level, with progressive renal failure SPSS, Base 7.5 (SPSS Inc., Chicago, IL, USA).
being defined as an increase in serum creatinine above
this level when measured at three months (62 weeks)
RESULTSpostbiopsy. The known duration of HIV and duration
of azotemia are taken as the time period from the first Twenty-one eligible patients were identified. Thirteen
had received corticosteroid treatment, and eight had not.known positive HIV serology and first known persis-
tently abnormal serum creatinine level, respectively, to The demographic and clinical characteristics of the pa-
tients are shown in Tables 1 and 2. All of the subjectsthe time of renal biopsy. An infection was defined as
any episode of care in which at least one antimicrobial were black. The mean (range) time from initiation of
corticosteroid treatment to the reduction in corticosteroidagent was prescribed for the treatment of a documented
or suspected infection. Subsequent retreatment, after at dose to 10 mg was 3.8 (1.25 to 6.11) months. The mean
(range) total duration of continuous corticosteroid treat-least one week without antimicrobials, was considered
to be a separate infectious episode. The incidence of ment was 5.3 months (2.3 to 9.4) months. Two patients
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Table 1. Baseline demographics, comorbidities, and medication use
Steroid- Non-steroid-
treated group treated group P a
Number of subjects 13 8
Age years
mean (SD) 41.8 (8.1) 38.9 (3.7) NS
Male/female 8/5 6/2 NS
History of IVDA
N (%) 6 (46%) 8 (100%) NS
Duration of HIV months
Median (range) 14 (1–91) 10 (1–102) NS
Duration of azotemia months
Median (range) 9.5 (2–19) 8.5 (3–22) NS
Hepatitis B
N (% of group) 3 (23%) 5 (63%) NS
Hepatitis C
N (% of group) 6 (46%) 7 (88%) NS
Systolic BP
Mean (SD) 133 (21) 142 (12) NS
Diastolic BP
Mean (SD) 80 (18) 84 (17) NS
Treated with anti-hypertensives
ACE inhibitors N (% of group) 1 (8%) 0 (0%) NS
Other agents N (% of group) 6 (46%) 2 (25%) NS
Number of antiretrovirals per patient
0 4 (31%) 4 (50%)
1 5 (38%) 0 (0%) NS
2 4 (31%) 4 (50%)
Date of renal biopsy
1994–1995 4 (31%) 3 (38%) NS
1996–1997 9 (61%) 5 (62%)
aAssessed using independent t-test, Mann-Whitney U, Chi square test or Fisher’s exact test as appropriate
Abbreviations are: IVDA, intravenous drug use; NS, not significant.
Table 3. Number of renal biopsies with selectedTable 2. Baseline serum laboratory results
histologic characteristicsa
Steroid- Non-steroid-
treated group treated group P a Steroid- Non-steroid-
treated group treated group P
Creatinine mg/dL
Mean (SD) 6.2 (1.9) 6.8 (2.2) NS Global sclerosis 7 6 NS
Glomerular collapse 3 3 NSUrea nitrogen mg/dL
Mean (SD) 56.8 (22.1) 55.9 (15.3) NS Interstitial fibrosis 7 4 NS
Arteriolar hylinosis 3 2 NSAlbumin g/dL
Mean (SD) 2.7 (1.2) 2.8 (0.7) NS Dense deposits 2 2 NS
Tubulitis 8 3 NSProteinuria g/day
Median (range) 6.6 (0.4–19.1) 3.7 (0.75–15.6) NS aReported as being moderate, severe or advanced
CD4 count cells/lL
Median (range) 173 (7–496) 66 (2–267) NS
Viral RNAb 1000 copies/mL
Median (range) 83 (4–630) 25 (1–324) NS
aAssessed using independent t-test or Mann-Whitney U-test as appropriate The histologic diagnosis in all cases was that of HIVAN.
bData only available for 6 corticosteroid-treated and 4 non-corticosteroid- The median (intraquartile range) number of glomerulitreated subjects
per biopsy was 16.5 (12) for the corticosteroid-treated
group and 12 (38) for the non–corticosteroid-treated
group. As shown in Table 3 and in keeping with our(both corticosteroid treated) had additional short courses
clinical experience and that reported by others [7], thereof corticosteroids as adjuvant therapy in treatment of
was a considerable variability in the histologic expres-Pneumocystis carinii infection. One, more recently treated
sion. One corticosteroid-treated patient, whose diseasepatient, who relapsed three months after his initial course
course we have previously described [9], in addition toof corticosteroids, did receive a second course of treat-
the typical findings of HIVAN, had evidence of a throm-ment for three months and his renal function again im-
botic microangiopathy, while another had quite markedproved. Corticosteroids were discontinued when he was
mesangial hypercellularity. In both cases, however, thediagnosed as having central nervous system (CNS) toxo-
predominant disease process causing the renal insuffi-plasmosis, following which his renal function once again
deteriorated. ciency was believed on clinical and histologic grounds
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Table 5. Incidence of serious infection, hospitalizations andTable 4. Association of corticosteroid treatment with improvement
of renal outcome adjusted separately for potential duration of hospital stay
baseline confounders
Steroid- Non-steroid-
treated group treated group POdds
ratio 95% CI P
Total patient follow-up 46.6 pm 18.3 pm ,0.01
Incidence of infection 1 per 2.6 pm 1 per 2.3 pm NSSteroids (unadjusted) 16.5 1.8, 148.5 0.01
Steroids adjusted for serum creatinine 39.1 2.2, 688.7 0.01 Incidence of hospitalization 1 per 2.1 pm 1 per 2.0 pm NS
Number of in-hospital days 3.2 per pm 2.0 per pm ,0.05Steroids adjusted for 24-hour proteinuria 19.9 1.5, 265.9 0.02
Steroids adjusted for CD4 count 14.2 1.5, 132.4 0.02 Abbreviations are: pm, patient month of follow-up; NS, not significant.
Steroids adjusted for hepatitis B 12.3 1.3, 119.8 0.03
Steroids adjusted for hepatitis C 11.4 1.2, 112.4 0.04
Steroids adjusted for history of IVDA 15.0 1.0, 218.2 0.05
Abbreviations are: CI, confidence interval; IVDA, intravenous drug use.
and 0.3 mg/dL, respectively, in their serum creatinine
levels at follow-up and two treated patients who did
not maintain an improvement in their renal function
to three-months follow-up, despite both having initiallyto be HIVAN. Four patients had dense deposits present
on electron microscopy. These were vague mesangial responded to treatment, in one case dramatically so,
before relapsing as corticosteroid therapy was tapered.and paramesangial deposits that were felt to be nonspecific
in two of the corticosteroid-treated patients. One non– Follow-up 24-hour proteinuria data were available for
eight of the corticosteroid-treated patients at threecorticosteroid-treated patient, who was coinfected with
hepatitis C, had scattered immune deposits in a capillary months. The mean (95% CI) protein excretion in these
patients, as compared with baseline, decreased by 25.5and subepithelial location, while another non–corti-
costeroid-treated patient had mesangial and subendo- g/day (21.6, 29.4; P 5 0.01), despite the significant im-
provement in patients’ glomerular filtration rate. Datathelial dense deposits without any obvious clinical corre-
lates. were only available for one nontreated patient whose
level of proteinuria increased by 3.3 g/day; the absenceAt three months of follow-up, the degree of azotemia
had progressed in six of eight non–corticosteroid-treated of follow-up data for the remaining nontreated patients
reflects their rapid progression to actual or near dialysispatients but in only 2 of the 13 corticosteroid-treated
subjects. The relative risk of progressive azotemia with at which point estimating the degree of proteinuria was
not routinely performed.treatment was 0.20 (P , 0.05). In this study population,
this is equivalent to an 80% reduction in the probability The incidence of hospitalization and infections is
shown in Table 5. There were 18 infections in the cortico-of progressive azotemia in association with corticosteroid
treatment (95% CI for this change was 0.05, 0.76). This steroid-treated patients and 8 in the non–corticosteroid-
treated group. However, as a result of their longer renalassociation remained significant in a subgroup analysis
that excluded the two corticosteroid-treated patients survival, the follow-up period of the corticosteroid-treated
patients was significantly longer than for the nontreatedwith atypical features on light microscopy. The associa-
tion between corticosteroid treatment and renal outcome patients (46.6 patient months vs. 18.2 patient months).
Allowing for this difference in follow-up, the incidencefor the entire group (N 5 21) remained significant when
adjusted in separate logistic regression analyses for base- rates for both infection and hospitalization for the two
groups are almost identical. The etiology of infectionsline serum creatinine, 24-hour proteinuria, CD4 count,
hepatitis B, hepatitis C, and a history of intravenous drug included pneumonia (8 episodes, including 4 caused by
Pneumocystis carinii), upper respiratory tract (6 episodes),use (Table 4). On multivariate logistic modeling, using
backward stepwise variable selection from the previously Candida esophagitis (2 episodes), central nervous system
toxoplasmosis (2 episodes in one subject), pulmonarymentioned confounders, only corticosteroid treatment
(P 5 0.02) and baseline serum creatinine (P 5 0.10) aspergillosis (1 episode), septicemia (6 episodes), and
cellulitis (1 episode). There was a significant increase inwere retained within the model.
Among the non–corticosteroid-treated subjects, three the mean hospital stay in the corticosteroid-treated group,
although this was largely the result of three prolongedhad progressed to dialysis by three months, and of the
remaining five nondialyzed patients, the mean (95% CI) admissions of 18, 21, and 26 days, respectively.
Figure 1 shows the long-term follow-up of the studychange in serum creatinine, compared with baseline, was
1.46 mg/dL (20.56, 3.47). Among the corticosteroid- subjects. At six months, only one of the noncorticoste-
roid-treated patients but seven of the corticosteroid-treated group, no patient progressed to requiring dial-
ysis, while the mean change in serum creatinine was treated group continued to have independent renal func-
tion (P 5 0.06). The majority of subjects in both groups22.22 mg/dL (20.98, 23.45; P , 0.01). The exceptions
to these general trends were two non–corticosteroid- progressed to dialysis by one year, with many subse-
quently dying. Four patients died in the corticosteroid-treated patients who had minimal improvements of 0.2
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on the day of admission. She had been last treated with
corticosteroids five weeks previously and had had a serum
creatinine of 5.5 mg/dL two weeks prior to admission.
Three of the 13 treated patients (23%) continued to
have independent function beyond one year of follow-up.
One of these patients, whose renal biopsy showed mesan-
gial hypercellularity in addition to changes of HIVAN
had been intolerant of both angiotensin-converting en-
zyme (ACE) inhibitors and of losartan. He suffered from
slowly progressive azotemia and commenced dialysis after
29 months of follow-up. The remaining two subjects both
had pretreatment biopsies that showed HIVAN-associ-
ated collapsing glomerulopathy. One, who was intolerant
of ACE inhibitors and losartan, had a serum creatinine
of 1.0 mg/dL after 36 months of follow-up, and the second
who had been on ACE inhibitor for the prior 36 months,
had a serum creatinine 2.2 mg/dL at 44 months of follow-
up. Their baseline serum creatinine had been 4.7 and
4.6 mg/dL, respectively, with a documented progressive
deterioration in renal function in the months prior to
treatment. Neither patient had a history of heroin abuse.
There were no clinical or histologic features associated
with corticosteroid response in either the long-term re-
sponders nor in the corticosteroid group as a whole.
DISCUSSION
Our study demonstrates a strong association between
the preservation of independent renal function and treat-
ment with corticosteroids. These beneficial effects re-
mained significant in separate regression analyses ad-
justing for potential confounders, while corticosteroid
therapy was the only significant factor associated with
renal survival on multivariate logistic regression. As the
outcome of progressive azotemia occurred in a relatively
large proportion of study subjects during the period of
analysis, the calculated odds ratio does not accuratelyFig. 1. (A) Long-term follow-up of steroid-treated group (N 5 13).
(B) Long-term follow-up of the non–steroid-treated group (N 5 8). estimate the relative risk [15], although the relative risk
Symbols are: ( ) unknown; ( ) dead; ( ) dialysis; (h) renal survival. and odds ratio both remain valid, although qualitatively
different, measures of the association of treatment with
outcome [16]. While relapse was common post-treatment
or with dose reduction, approximately 20% of our corti-treated group during the course of the study. Three pa-
costeroid-treated group had continued independent re-tients withdrew from active medical support: One was
nal function after over two years of follow-up. The de-on 5 mg of prednisone following a corticosteroid taper
gree of proteinuria significantly decreased in all of thefor pneumocystis pneumonia. He had invasive aspergil-
corticosteroid-treated patients for whom data were avail-losis and a serum creatinine of 3.3 mg/dL. The second
able. These benefits were not associated with an in-had disseminated infection with acanthamoeba; he was
creased risk of infection or hospitalization.six-months poststudy entry and three months off cortico-
Appel and Neill were the first to describe treatmentsteroids with a serum creatinine of 4.3 mg/dL. The third
with corticosteroids in an HIV-positive patient with ne-had persistent respiratory failure despite a prolonged
phropathy [17]. Their patient had an IgM nephropathyhospital course; his serum creatinine was 7.6 mg/dL at
and was successfully treated with 60 mg prednisone fortime of admission, having discontinued corticosteroids
eight months, without any overt complications. In a moretwo months prior to the terminal hospitalization. The
recent report, Watterson, Detwiller, and Bolin describefourth patient presented to the hospital in septic shock
with a serum creatinine of 11.9 mg/dL and died later the successful treatment of a patient with classic histo-
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logic and clinical features of HIVAN [10]. The patient able response was not seen [18–20]. The reasons for this
difference in response are not known.relapsed after four months of discontinuing corticoste-
The mechanism of action of corticosteroids in theroids but responded to the reintroduction of treatment.
treatment of HIVAN, as in non–HIV-associated focal glo-Smith et al prospectively studied 20 corticosteroid-
merular sclerosis, remains largely speculative. Increasingtreated subjects with HIVAN (17 biopsy proven) with a
evidence from transgenic mouse experiments implicatesmedian follow-up of 44 weeks [7]. Their study population
direct viral involvement in the pathogenesis of HIVANwas predominantly black, with moderate or advanced
[reviewed in 21]. However, while not sufficient for theazotemia and low CD4 counts (mean 58 cells/mL). Only
development of HIVAN, the presence of immune dys-one patient was an intravenous drug user. In addition to
regulation and the production of proinflammatory cyto-the typical findings of HIVAN, three cases had mesangial
kines, such as interleukin-6 [22], may play a necessarycell proliferation, and eight cases had rare to occasional
role in the progression of the glomerular lesion. We haveelectron-dense deposits. Unfortunately, their study did
previously reported that in comparison with a pretreat-not have a control group. Patients were treated with
ment renal biopsy from a patient with HIVAN, a postcor-prednisone 60 mg for between 2 and 11 weeks and then
ticosteroid treatment biopsy revealed a substantial de-had their corticosteroids tapered over a 2- to 26-week
crease in the degree of interstitial inflammation but noperiod. Eighteen patients had an initial response to treat-
evidence of improvement in the glomerular pathologyment, with a significant reduction in the serum creatinine
[9]. It is thus possible that corticosteroid therapy acts byand, in 11 cases where paired samples were available, in
limiting interstitial inflammation and by attenuating thetheir 24-hour urine protein excretion. Five of nine pa-
production of inflammatory mediators. What factors maytients who relapsed were retreated, all of whom re-
be involved in determining the duration of this responsesponded, although one subsequently relapsed for a third
are unknown.time. Several infectious episodes were noted during the
As all of our patients had undergone renal biopsytreatment period, but in the absence of a control group,
immediately prior to starting treatment, we were ableno determination could be made as to the influence of
to confirm the diagnosis of HIVAN and outrule anycorticosteroid treatment in predisposing to the develop-
alternative acute reversible process causing the pretreat-ment of these infections, in this group with significant
ment renal dysfunction. Moreover, as we had a contem-pre-existent HIV-related immune suppression.
poraneous control group, we were able to compare bothIn a recent report by Laradi et al, 15 of 108 patients
outcome and complication rates in the corticosteroid-with biopsy-proven HIVAN were treated with cortico-
treated and the non–corticosteroid-treated groups. Us-steroids [8]. The study population was 97% black, with
ing our limited-duration corticosteroid treatment, we did
11% of the subjects having a history of intravenous drug
not observe any increase in the incidence of infections
use. The median CD4 counts of 48.5 cell/mL. Initial corti- or hospitalizations in the corticosteroid treated group.
costeroid therapy was 1 mg/kg for two to six weeks, with This acceptable side-effect profile of corticosteroids in
a median total duration of treatment of 6.4 months and the treatment of HIV-infected patients is in keeping with
a range of 1 to 33 months. While for unclear reasons the recommendations of an expert panel regarding the
corticosteroid therapy had no effect on protein excretion, use of corticosteroids in the treatment of Pneumocystis
it did significantly decrease the incidence of progression infection [23]. It is also in keeping with clinical experi-
to ESRD, [relative risk 0.29 (95% CI 0.09 to 0.91), P 5 ence of corticosteroid therapy in patients with HIV-asso-
0.03]. This reduction in the relative risk is of a similar ciated thrombocytopenia [24] and esophageal ulcers [25].
magnitude as that seen in our study. Using a multivariate Our study was conducted prior to the widespread use
model, in addition to corticosteroid therapy, the patient’s of highly active antiretroviral therapy, while our ability to
CD4 count, creatinine, degree of proteinuria, and hemo- prescribe ACE inhibitors was limited by the high baseline
globin were predictive of renal death. At the last reported serum creatinines in both groups. Kimmel, Mishkin, and
follow-up, 6 of 15 corticosteroid-treated patients had died. Umana prospectively studied nine captopril-treated pa-
The overall mortality was not influenced by cortico- tients with biopsy-proven HIVAN and compared their
steroid therapy. Three nonfatal complications were re- renal survival with a similar number of non–captopril-
ported that were attributed to corticosteroid therapy, treated patients [26]. Median renal survival increased
namely, corticosteroid-associated psychosis, osteonecrosis from 30 to 83 days, while two of the treated patients had
of a femoral head, and septic arthritis. However, compar- long-lasting remissions. Treatment with ACE inhibitors
ative data for the infection rate between corticosteroid was significantly associated with renal survival. These
and noncorticosteroid treated patients were not reported. results are supported by a study by Burns et al, who
Corticosteroid treatment has been attempted, in an treated 12 patients with fosinopril for 12 weeks and com-
uncontrolled fashion, in a small number of children with pared their outcome with 8 patients who declined treat-
ment with the ACE inhibitor [27]. Treatment with ACEHIVAN. In contrast to the experience in adults, a favor-
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inhibition was associated with a significant reduction in costeroid therapy by our clinical guidelines. As clinical
proteinuria and stabilization of renal function. Of note, practice regarding the use of corticosteroids in subjects
in both of these studies of ACE inhibitors, the subjects with HIVAN is not uniform within our institution, the
had less severe renal dysfunction than in either our cur- decision to offer corticosteroid therapy was, in many
rent report or in the two previously reported case series cases, dependent on which attending nephrologist was
of corticosteroid treatment [7, 8]. The mean serum creati- on clinical service at a given time and was thus essentially
nine in the study by Kimmel, Mishkin, and Umana was haphazard. Our study’s small sample size limits our abil-
3.55 mg/dL, and all of subjects in the study by Burns et ity to simultaneously adjust for different potential con-
al had a baseline serum creatinine of less than 2 mg/dL. founders. We did, however, adjust separately for what
In contrast, Smith et al reported a mean pretreatment would appear to be the most clinically relevant con-
serum creatinine of 8.4 mg/dL [7] and Laradi et al a founders following which in each case the association of
median baseline serum creatinine of 6.2 mg/dL [8]. Also, corticosteroid treatment with outcome remained signifi-
in contrast to the results obtained in these studies with cant. Despite these measures, residual confounding is
corticosteroids, treatment with ACE inhibitors was asso- undoubtedly present in our analysis. We do not believe,
ciated with a stabilization but not a significant improve- but are unable to prove that these influences are of suffi-
ment in the degree of renal dysfunction.
cient magnitude as to explain completely the observed
Several case reports [28–30] and a prospective study
beneficial effects of corticosteroid therapy.[31] suggest a beneficial effect of antiretroviral therapy
In conclusion, our study supports a limited course ofon the outcome of HIVAN. The evidence of direct viral
corticosteroid therapy in selected patients with progres-involvement in the pathogenesis of HIV in transgenic
sive azotemia and HIVAN as being both beneficial andmouse models provides a clear rationale for the use of
safe. The results reported here justify continued consid-antiretroviral agents as therapy for HIVAN. The effec-
eration of the role that corticosteroids may have in thetiveness of highly active antiretrovirals in the treatment
medical management of patient with HIVAN and pro-of HIVAN has been suggested by a recent case report
gressive azotemia. A more exact evaluation of the effec-regarding two subjects (abstract; J Am Soc Nephrol 10:
tiveness and safety of corticosteroids, free from the limi-A0603, 1999). The natural history of HIVAN and the
tations alluded to previously in this article, requires apotential benefits of corticosteroid therapy, in the setting
prospective randomized multicenter trial. The AIDSof these newer therapies, are unknown. It is our clinical
clinical trials group had designed such a trial in 1995, butimpression, however, that both combination antiretrovi-
ral and ACE inhibition treatment slow but do not, in it was subsequently abandoned because of poor patient
many cases, abolish progression of HIVAN. recruitment. There remains a clear need for such a pro-
Our current policy toward the treatment of biopsy- spective trial examining the efficacy of corticosteroid in
proven HIVAN is to use ACE inhibitors and highly a cohort of patients on optimal antiretroviral and ACE
active antiretroviral therapy aggressively, as tolerated. In inhibitor therapy. In addition, research is required to
patients who progress, despite the previously mentioned examine the optimal method of maintaining disease re-
therapeutic strategy, we offer corticosteroid therapy, mission once it is achieved. Despite the difficulties inher-
provided the patient has been abstinent from illicit drug ent in such a project, the need for such research is under-
use for at least two months, has a demonstrated history scored by the increasing number of subjects who are at
of compliance with medical follow-up, has had no recent risk for developing HIVAN. As improvements in the
clinical infection, and has had no history of subclinical infectious complications of HIV result in more patients
chronic infection. We use a similar protocol to that out- surviving longer and thus being susceptible to the late
lined in the Methods section, although the duration and
manifestations of HIV, the incidence of HIVAN may be
intensity of treatment are individualized. Patients are
expected to increase with time. In the developed world,closely followed with initial weekly visits to either the
dialysis provides a treatment option for patients withnephrology or infectious disease clinic. Therapy is dis-
HIVAN-induced ESRD, albeit at a considerable cost;continued if no response is seen within one month. In
however, throughout much of the developing world, pro-patients who relapse, we consider reintroduction cortico-
gressive unchecked azotemia is likely to prove lethalsteroids, depending on the perceived potential risks and
because of the limited availability of dialysis. As thebenefits of further treatment in comparison with the op-
survival of HIV-infected patients in these areas im-tion of maintenance dialysis.
proves, the development of HIVAN, especially in theLimitations of our study result from it being retrospec-
genetically susceptible populations of Africa and the Ca-tive and nonrandomized, and thus being susceptible to
ribbean, is likely to lead to increasing morbidity anda range of potential biases, such as bias in the selection
mortality, and the medical management of HIVAN isof patients for corticosteroid therapy. However, all of
the subjects included in the study were eligible for corti- likely to assume an increasing global importance.
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